Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer

Overview of attention for article published in Clinical Cancer Research, November 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter: 32 X users
patent: 2 patents

facebook: 1 Facebook page

Readers on

mendeley: 50 Mendeley

So far, Altmetric has seen 35 X posts from 32 X users, with an upper bound of 169,054 followers.

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer https://t.co/05bm5jwqYi

RT @shilpaonc: Thanks #clincancerresearch @AACR for publishing our manuscript on seviteronel, novel dual AR antagonist/CYP17 inhibitor in #…

RT @SoaresAndrey: Great job. And seems that it works in some important AR mutations as T878A and F876L https://t.co/oltRCYjvxz

RT @shilpaonc: Thanks #clincancerresearch @AACR for publishing our manuscript on seviteronel, novel dual AR antagonist/CYP17 inhibitor in #…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 31 additional X posts.